WINT

Windtree Therapeutics, Inc. (WINT) | Rumor.io

Windtree Therapeutics

WINT

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)0%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about WINT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.01

Feb 14

Windtree Therapeutics, Inc. (WINT) is showing signs of growth, with its token price increasing by 121% to $0.0011 on $178k volume.
WINT is expected to take the #2 spot soon, potentially surpassing other assets like $NOX and $ETHY.
WhaleintelAI, an on-chain whale tracker, is highlighting WINT's significant whale activity, with the platform providing premium analytics for Virtuals Protocol ecosystem launches.

Generated by AI

Sentiment

Of the messages about WINT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	87.8% +4.28
Bearish	—	—	—	12.2% -4.28

Bullish· Nov 28

Windtree Therapeutics, Inc. (WINT) is showing steady growth at $0.50 USD and focusing on upcoming collaborations for a 25% mindshare boost.
WINT's integration with AI platforms is promising for user insights, and the company is revolutionizing crypto trading with real-time data intelligence.
WINT is tracking whales, delivering actionable alpha signals, and its partnership with ARBUS is driving growth in the ecosystem, with a real utility for staying ahead of the market.

Bearish· Aug 20

Windtree Therapeutics, Inc. (WINT) has been delisted, resulting in significant losses for investors, with some reporting losses of over $430k.
The company's CFO, John Busch, has been accused of being behind the theft of investors' funds, with some calling for him to serve prison time.
The stock has experienced a massive 79% crash after the delisting announcement, with some traders calling it a "SCAM" and warning others to avoid it.

Generated by AI

Topics

Of the messages about WINT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	41.14%
Announcements	—	—	—	20.72%
Controversies	—	—	—	0.22%
Earnings	—	—	—	0.04%
Macro	—	—	—	28.35%
Technical Analysis	—	—	—	9.52%

Analysts· Jun 4

Oppenheimer analyst Leland Gershell initiates coverage on Windtree Therapeutics with an Outperform rating and a price target of $8.
Windtree Therapeutics shares are trading higher by 32% at $2.63 in premarket session after Oppenheimer initiated coverage with an Outperform rating and an $8 price target.
The stock has a 52-week-high of $10.06 and a 52-week-low of $1.58, with an EPS of $0.51 in the first quarter.

Announcements· Jul 24

Windtree Therapeutics, Inc. (WINT) has entered into a Common Stock Purchase Agreement for up to $500 million to establish an equity line of credit and bolster its BNB cryptocurrency treasury strategy.
The company will allocate 99% of the proceeds from the equity line of credit and a $20 million stock purchase agreement to acquiring BNB cryptocurrency, with up to $700 million committed to BNB acquisitions.
Windtree Therapeutics has announced up to $520 million in new funding to amplify its BNB cryptocurrency treasury strategy, with the proceeds to be used to buy BNB.

Technical Analysis· Jul 17

$WINT has a wedge breakout and is up 10%+, with key levels to watch for a potential move.
The RSI and MACD are swollen, indicating a possible correction, and the Weekly Parabolic SAR has flipped to an uptrend signal.
A break over $1.32 will send $WINT up, with strong support at $1.25 and a possible retest of the high of the day.

Generated by AI

Community

Of the messages about WINT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	39.6%
Newcomers	—	—	—	60.4%

Regulars· Sep 17

The regulars are focusing on finding undervalued plays in addition to their existing positions in WINT.
They suggest backing the top 1-3 stocks and then looking for undervalued plays.
WINT is mentioned alongside $predi and $billy as stocks the regulars own or are looking to add to their portfolio.

Newcomers· Aug 20

The newcomer is focusing on the delisting of Windtree Therapeutics, Inc. (WINT) from Nasdaq on August 21, 2025, due to non-compliance.
The delisting is seen as a negative event, potentially causing a bounce setup to be a trap, and some users are advising others not to touch WINT.
Some users are comparing the experience and conviction required for successful trades, mentioning that experience leads to stronger conviction, and stronger conviction leads to greater rewards, as seen in a few days ago when both WINT and AIN plays paid off.

Generated by AI

Also Discussed

Investors talking about WINT also mention

#	Name	Attention
1	Interactive Strength Inc.TRNR	0%0
2	AREB - American Rebel Holdings, Inc.	——
3	Tenon Medical, Inc.TNON	0%new
4	CNS Pharmaceuticals Inc.CNSP	0%0
5	Expion360 Inc.XPON	0%0
6	AMREP CorpAXR	0%0
7	BIOS - BioPlus Acquisition Corp.	——
8	Invesco Trust for Investment Grade MunicipalsVGM	0%0
9	iShares MSCI Global Gold Miners ETFRING	0%0
10	Able View Global Inc. Class B Ordinary SharesABLV	0%0